317 related articles for article (PubMed ID: 17956279)
1. hERG channel trafficking: novel targets in drug-induced long QT syndrome.
Dennis A; Wang L; Wan X; Ficker E
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1060-3. PubMed ID: 17956279
[TBL] [Abstract][Full Text] [Related]
2. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes.
Guo J; Massaeli H; Li W; Xu J; Luo T; Shaw J; Kirshenbaum LA; Zhang S
J Pharmacol Exp Ther; 2007 Jun; 321(3):911-20. PubMed ID: 17377062
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG.
Dennis AT; Nassal D; Deschenes I; Thomas D; Ficker E
J Biol Chem; 2011 Sep; 286(39):34413-25. PubMed ID: 21832094
[TBL] [Abstract][Full Text] [Related]
4. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
5. [Progress in research on defective protein trafficking and functional restoration in HERG-associated long QT syndrome].
Fang P; Lian J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Feb; 33(1):101-4. PubMed ID: 26829745
[TBL] [Abstract][Full Text] [Related]
6. Pentamidine-induced long QT syndrome and block of hERG trafficking.
Kuryshev YA; Ficker E; Wang L; Hawryluk P; Dennis AT; Wible BA; Brown AM; Kang J; Chen XL; Sawamura K; Reynolds W; Rampe D
J Pharmacol Exp Ther; 2005 Jan; 312(1):316-23. PubMed ID: 15340016
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms underlying probucol-induced hERG-channel deficiency.
Shi YQ; Yan CC; Zhang X; Yan M; Liu LR; Geng HZ; Lv L; Li BX
Drug Des Devel Ther; 2015; 9():3695-704. PubMed ID: 26229434
[TBL] [Abstract][Full Text] [Related]
8. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
Thomas D; Karle CA; Kiehn J
Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
[TBL] [Abstract][Full Text] [Related]
9. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
[TBL] [Abstract][Full Text] [Related]
10. Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.
Hancox JC; Mitcheson JS
Br J Pharmacol; 2006 Nov; 149(5):457-9. PubMed ID: 16967047
[TBL] [Abstract][Full Text] [Related]
11. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
12. hERG: protein trafficking and potential for therapy and drug side effects.
Staudacher I; Schweizer PA; Katus HA; Thomas D
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):23-30. PubMed ID: 20047143
[TBL] [Abstract][Full Text] [Related]
13. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
14. Involvement of caveolin in probucol-induced reduction in hERG plasma-membrane expression.
Guo J; Li X; Shallow H; Xu J; Yang T; Massaeli H; Li W; Sun T; Pierce GN; Zhang S
Mol Pharmacol; 2011 May; 79(5):806-13. PubMed ID: 21278233
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Rajamani S; Eckhardt LL; Valdivia CR; Klemens CA; Gillman BM; Anderson CL; Holzem KM; Delisle BP; Anson BD; Makielski JC; January CT
Br J Pharmacol; 2006 Nov; 149(5):481-9. PubMed ID: 16967046
[TBL] [Abstract][Full Text] [Related]
16. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
Gintant GA; Su Z; Martin RL; Cox BF
Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
[TBL] [Abstract][Full Text] [Related]
17. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
18. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
19. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
Guthrie H; Livingston FS; Gubler U; Garippa R
J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341
[TBL] [Abstract][Full Text] [Related]
20. HERG channel trafficking.
Ficker E; Dennis A; Kuryshev Y; Wible BA; Brown AM
Novartis Found Symp; 2005; 266():57-69; discussion 70-4, 95-9. PubMed ID: 16050262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
